Navigation Links
Bristol-Myers Squibb and Simcere Enter Partnership to Co-Develop and Co-Commercialize Orencia(R) SC (abatacept) in China
Date:6/14/2013

>

Mr. Hongquan Liu further commented, "Moving forward, we will continue to execute on our partnering strategy and to bring in more late-stage programs and products already approved outside of China, to complement our R&D pipeline and strengthen our in-market portfolio."

"We are pleased to partner with Simcere on Orencia SC, moving beyond our companies' original focus on early development activities to a partnership focused on the clinical development and commercialization of one of our currently marketed products," said Beatrice Cazala, executive vice president, Commercial Operations. "If successful, not only could Orencia SC bring a new option to Chinese patients suffering from rheumatoid arthritis, but also it could become Bristol-Myers Squibb's first biologic medicine for the Chinese market."

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com or follow us on Twitter at http://twitter.com/bmsnews.

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group (NYSE: SCR, Simcere) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective therapy, including cancer, strokes, cardiovascular diseases, infectious diseases and pain. For more information about Simcere Pharmaceutical Group, please visit

SOURCE Simcere Pharmaceutical Group
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Bristol-Myers Squibb to Present New Data on ORENCIA(R)? (abatacept) at the European League Against Rheumatism (EULAR) 2012 Congress
2. Amylin Pharmaceuticals, Inc. Shareholder Alert: Bernstein Liebhard LLP Announces Investigation Of Acquisition By Bristol-Myers Squibb Company
3. Alder Biopharmaceuticals Receives $3.5 Million Milestone Payment from Bristol-Myers Squibb for Initiation of Phase 2 Clinical Trial of ALD518/BMS-945429 in Crohns Disease
4. Life Technologies to Partner with Bristol-Myers Squibb for Companion Diagnostics Development
5. StockCall Insight into Eli Lilly, Bristol-Myers Squibb, Astex Pharmaceuticals and Raptor Pharmaceuticals
6. Ambrx Initiates Collaboration with Bristol-Myers Squibb for Discovery, Development of Next-Generation Antibody Drug Conjugates
7. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
8. Simcere Pharmaceutical Group Provides Notice of Annual General Meeting
9. Simcere Pharmaceutical Group to Announce Second Quarter 2012 Financial Results on Friday, August 10, 2012
10. Simcere Pharmaceutical Group Reports Preliminary Unaudited Second Quarter 2012 Results
11. Simcere Pharmaceutical Group Announces Appointment of New Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... , September 17, 2014 ... GRC 17536, has shown positive data in a Phase ... diabetic neuropathy , Glenmark Pharmaceuticals ... Potential Ankyrin 1 (TRPA1) antagonist, GRC 17536 has shown ... controlled, multi-centre, proof of concept study conducted on 138 ...
(Date:9/17/2014)...  Members of the physician IT team at ... today that the enterprise is working with ... capabilities and provide immediate cluster fail over in ... the Dicom Systems enterprise imaging solutions will be ... more effectively deliver the right images to the ...
(Date:9/17/2014)... 2014 An analysis done by the CVS ... (sofosbuvir), a new and expensive treatment for Hepatitis C ... last several months (May through August 2014) there has ... utilization. This suggests another surge of patients will begin ... similar efficacy and shorter duration are introduced in the ...
Breaking Medicine Technology:Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study 2Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study 3Dicom Systems' Innovative Software Provides Enhanced Imaging Sharing Capabilities, as Well as Connection Reliability in the Case of Network Failure 2Dicom Systems' Innovative Software Provides Enhanced Imaging Sharing Capabilities, as Well as Connection Reliability in the Case of Network Failure 3CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies 2CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies 3CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies 4
... Event for Congressional Members and Staff Will Focus on Advances ... Research and Treatment of Lung Cancer in ... CTIC; MTAX:), along with the Society for Women,s Health,Research, the ... "Lung Cancer: Being Female Matters to Research," on,Capitol Hill to ...
... in cSSSI, CAMBRIDGE, Mass., Sept. 13 ... Phase 2 trial,investigating the safety and efficacy of ... of Complicated Skin and Skin Structure,Infections (cSSSI), or ... positive infections. This Phase 2 study is ...
Cached Medicine Technology:Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill 2Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill 3Targanta Initiates Phase 2 Oritavancin Infrequent Dosing Study 2Targanta Initiates Phase 2 Oritavancin Infrequent Dosing Study 3
(Date:9/17/2014)... like the ideas of a science fiction writer, ... exciting new approach to imaging local and metastatic ... cancer, scientists at Virginia Commonwealth University Massey Cancer ... Hopkins Medical Institutions have provided proof-of-principle of a ... ability to see tumors that have metastasized to ...
(Date:9/17/2014)... 17, 2014 Catalent Pharma Solutions, ... and development solutions for drugs, biologics and consumer ... an integrated service and technology offer based on ... from the company’s 450,000 sq. ft. Kansas City, ... to integrate optimal formulation, development, analytical expertise, scale ...
(Date:9/17/2014)... 2014 (HealthDay News) -- Positive messages about the health ... the habit, a new study suggests. Although smokers ... "loss-framed" messages about the harmful effects of smoking, researchers ... want benefit more from "gain-framed," or positive, messages about ... concluded that using a mix of both types of ...
(Date:9/17/2014)... New York, New York (PRWEB) September 17, 2014 ... ) filings involving the Conserve line of metal-on-metal ... litigation now underway in U.S. District Court, Northern ... to an updated Case List issued by the ... 15, 2014, at least 397 product liability claims ...
(Date:9/17/2014)... TX (PRWEB) September 17, 2014 Smart ... Editor’s Picks by Progressive Grocer, a leading trade magazine ... was awarded for originality and flavor, among other attributes. ... as an Editor’s Pick in the September print issue ... Grocer website. , The pizza won based on its ...
Breaking Medicine News(10 mins):Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 3Health News:New OptiPact™ Technology Introduced by Catalent 2Health News:More Than One Kind of Message May Convince Smokers to Quit, Study Says 2Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 2Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 3Health News:Smart Flour Foods Wins 2014 Progressive Grocer Editor’s Pick Award 2
... A new technology called the Cone beam computerized tomography ... to diagnose complicated oral problems.// ,J. Martin ... at the Case Western Reserve University School of Dental ... department of dental health and biological sciences at the ...
... two protein complexes which is found to protect cell ... number of chromosomes leading to cell instability which leads ... research team from Mayo Clinic have found that the ... which maintains the euploidy state in the cell and ...
... The waiting times at Ontario’s hospitals are getting longer, according ... revealed by Elizabeth Witmer, the Conservative health critic.// The waiting ... and September 2005 for cancer surgery, while it rose from ... time increased to 22 days for cardiac surgeries, while in ...
... genetic code is reported to have been cracked by ... faster diagnosis and treatment of the ailment which causes ... Jewish General Hospital’s Dasval. The strain has caused infections ... The search can now commence for the other antibiotic ...
... Institute (SERI) found that increasing the contrast of details ... the visually impaired. // ,The U.S. study provides ... help millions suffering eye diseases. People who may benefit ... degeneration, diabetic retinopathy and other causes of low vision. ...
... National Laboratories, Gerry Yonas was the first to visualize a need ... the development of the BiNational Sustainability Laboratory (BNSL), which extends over ... mainly augment the border security force and deal with terrorism ... ,The monetary inputs for the lab come from USA, ...
Cached Medicine News:Health News:New Computerized Imaging Systems Help In Better Dental Treatment Planning 2Health News:Visually impaired prefer specially enhanced TV 2Health News:Visually impaired prefer specially enhanced TV 3
Cold light source single outlet....
Cold light source triple outlet....
Cold light source single outlet....
... is a state of the ... source with an integrated intensity ... to connect optical fiber light ... itself from all others by ...
Medicine Products: